Aditxt, Inc. and SphereDX Launch AditxtScore™ for COVID-19 in Kentucky, Ohio and Indiana to Address Individual Immune Status Uncertainty and Help Evaluate Cadence for Booster Shots
September 09 2021 - 8:26AM
Business Wire
Initial AditxtScore testing found one-third of
fully vaccinated assisted living community residents needed booster
vaccinations to strengthen individual antibody response
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company with a
mission to improve the health of the immune system, today announced
a partnership with SphereDX, an advanced clinical diagnostic lab
focusing on next-generation genomic and metabolomic clinical
testing, to offer its AditxtScore™ for COVID-19. The AditxtScore
for COVID-19 is a more comprehensive immune response monitoring
tool that tracks multiple combinations of antibody and neutralizing
antibody responses against several different antigens. This makes
it possible to assess the strength of an individual’s immune
response to COVID-19.
Under the agreement, SphereDX will make the AditxtScore for
COVID-19 available throughout its laboratory locations serving
Kentucky, Ohio and Indiana. The initiative is part of Aditxt’s
ongoing effort to expand its immune monitoring network
nationwide.
“There is so much uncertainty out there right now with Kentucky
hospitals experiencing critical staffing shortages, kids starting
to go back to school, and businesses re-opening during a dramatic
surge in COVID-19 cases. By making the AditxtScore for COVID-19
available to our providers and patients, we are able to offer the
most detailed, accurate view of individual immune response, giving
people the facts they need to make informed decisions about booster
vaccinations, return-to-work protocols, mask use and other
preventive measures,” said Bobby Sturgeon, SphereDX CEO. “The value
of this high-fidelity type of antibody testing became immediately
clear when we conducted a pilot program in a local assisted living
facility, which showed us that roughly one-third of fully
vaccinated residents had suboptimal immune responses and required
booster shots.”
SphereDX conducted a pilot program deploying the AditxtScore for
COVID-19 in a group of area assisted living facilities. Testing a
total of 99 fully vaccinated residents ages 63 to 99, the results
showed that 33.3% of the residents tested had a suboptimal immune
response. Of that group, 8.1% showed no discernable immune response
to COVID-19. The CDC has recommended that people with moderately to
severely compromised immune systems receive an additional dose of
the mRNA COVID-19 vaccine.
“If we really want to get ‘back to normal’ with confidence, we
are going to need personalized immune testing that delivers
detailed information on the strength and durability of each
individual’s immune response,” said Amro Albanna, Co-founder and
Chief Executive Officer of Aditxt. “We are thrilled to be working
with SphereDX to bring that level of certainty and confidence to
the people of Kentucky, Ohio and Indiana.”
AditxtScore for COVID-19, which was first introduced in August
2020, differentiates itself from traditional antibody tests by
delivering a detailed view of an individual’s immune response to
multiple antigens associated with COVID-19. This multiplex approach
to capturing the full spectrum of biomarkers associated with
COVID-19 delivers a highly detailed snapshot of an individual’s
immune response in a single test cycle. It also includes the
ability to measure neutralizing antibodies, the subset of
virus-specific antibodies that block infection by interfering with
cell entry of virus particles.
The level of precision in AditxtScore for COVID-19, along with
its ability to measure the neutralizing activity of IgG, IgM and
IgA isotopes, can provide clinicians with the data they need to
understand the strength and quality of each individual’s immune
response to COVID-19. This information can be used to guide further
intervention for those who have not developed a strong immune
response and to reassure those who have developed a strong response
that no further action is required.
This information is particularly important for the millions of
immunocompromised patients who may not develop an adequate immune
response to vaccination or exposure for multiple reasons,
including: immunosuppressive disease, immunosuppressant
medications, anti-cancer medications affecting immune function, or
the presence of long-term chronic disease that has exhausted the
body’s natural immune response capacity.
AditxtScore for COVID-19 is offered through authorized channel
partners. To find an AditxtScore Channel Partner near you, please
visit www.aditxtscore.com. AditxtScore for COVID-19 is available
for use as a CLIA-validated laboratory developed test (LDT). This
test is not for self-diagnosis and is not cleared or approved by
the FDA.
About Aditxt:
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt’s immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt’s immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s intellectual property position; the Company’s ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company’s results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
titled “Risk Factors” in the Company’s most recent Annual Report on
Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005562/en/
Media and Investor Relations Contact: Sunny Uberoi Chief
Communications Officer Aditxt ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024